Search

Your search keyword '"Vaze, Anjali"' showing total 27 results
Start Over Author "Vaze, Anjali"
27 results on '"Vaze, Anjali"'

3. Supplementary Tables from Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Author

Gerber, David E., primary, Infante, Jeffrey R., primary, Gordon, Michael S., primary, Goldberg, Sarah B., primary, Martín, Miguel, primary, Felip, Enriqueta, primary, Martinez Garcia, Maria, primary, Schiller, Joan H., primary, Spigel, David R., primary, Cordova, Julie, primary, Westcott, Valerie, primary, Wang, Yulei, primary, Shames, David S., primary, Choi, YounJeong, primary, Kahn, Robert, primary, Dere, Randall C., primary, Samineni, Divya, primary, Xu, Jian, primary, Lin, Kedan, primary, Wood, Katie, primary, Royer-Joo, Stephanie, primary, Lemahieu, Vanessa, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Maslyar, Daniel, primary, Humke, Eric W., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure from Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Author

Herrera, Alex F., primary, Patel, Manish R., primary, Burke, John M., primary, Advani, Ranjana, primary, Cheson, Bruce D., primary, Sharman, Jeff P., primary, Penuel, Elicia, primary, Polson, Andrew G., primary, Liao, Chen Di, primary, Li, Chunze, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Samineni, Divya, primary, Elstrom, Rebecca, primary, Cooper, James, primary, and Diefenbach, Catherine, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 1 from Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Author

Gerber, David E., primary, Infante, Jeffrey R., primary, Gordon, Michael S., primary, Goldberg, Sarah B., primary, Martín, Miguel, primary, Felip, Enriqueta, primary, Martinez Garcia, Maria, primary, Schiller, Joan H., primary, Spigel, David R., primary, Cordova, Julie, primary, Westcott, Valerie, primary, Wang, Yulei, primary, Shames, David S., primary, Choi, YounJeong, primary, Kahn, Robert, primary, Dere, Randall C., primary, Samineni, Divya, primary, Xu, Jian, primary, Lin, Kedan, primary, Wood, Katie, primary, Royer-Joo, Stephanie, primary, Lemahieu, Vanessa, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Maslyar, Daniel, primary, Humke, Eric W., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Data from Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Author

Herrera, Alex F., primary, Patel, Manish R., primary, Burke, John M., primary, Advani, Ranjana, primary, Cheson, Bruce D., primary, Sharman, Jeff P., primary, Penuel, Elicia, primary, Polson, Andrew G., primary, Liao, Chen Di, primary, Li, Chunze, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Samineni, Divya, primary, Elstrom, Rebecca, primary, Cooper, James, primary, and Diefenbach, Catherine, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 2 from Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Author

Gerber, David E., primary, Infante, Jeffrey R., primary, Gordon, Michael S., primary, Goldberg, Sarah B., primary, Martín, Miguel, primary, Felip, Enriqueta, primary, Martinez Garcia, Maria, primary, Schiller, Joan H., primary, Spigel, David R., primary, Cordova, Julie, primary, Westcott, Valerie, primary, Wang, Yulei, primary, Shames, David S., primary, Choi, YounJeong, primary, Kahn, Robert, primary, Dere, Randall C., primary, Samineni, Divya, primary, Xu, Jian, primary, Lin, Kedan, primary, Wood, Katie, primary, Royer-Joo, Stephanie, primary, Lemahieu, Vanessa, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Maslyar, Daniel, primary, Humke, Eric W., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

9. A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia

Author

Daver, Naval, Salhotra, Amandeep, Brandwein, Joseph M., Podoltsev, Nikolai A., Pollyea, Daniel A., Jurcic, Joseph G., Assouline, Sarit, Yee, Karen, Li, Mengsong, Pourmohamad, Tony, Samineni, Divya, Sumiyoshi, Teiko, Vaze, Anjali, Dere, Randall C., Ma, Connie, and Cooper, James

Subjects
Correspondence, Correspondences
Published
2021

10. Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Author

Herrera, Alex F., primary, Patel, Manish R., additional, Burke, John M., additional, Advani, Ranjana, additional, Cheson, Bruce D., additional, Sharman, Jeff P., additional, Penuel, Elicia, additional, Polson, Andrew G., additional, Liao, Chen Di, additional, Li, Chunze, additional, Schuth, Eva, additional, Vaze, Anjali, additional, Samineni, Divya, additional, Elstrom, Rebecca, additional, Cooper, James, additional, and Diefenbach, Catherine, additional

Published
2022
Full Text
View/download PDF

11. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

Author

Liu, Joyce, primary, Burris, Howard, additional, Wang, Judy S., additional, Barroilhet, Lisa, additional, Gutierrez, Martin, additional, Wang, Yulei, additional, Vaze, Anjali, additional, Commerford, Renee, additional, Royer-Joo, Stephanie, additional, Choeurng, Voleak, additional, Humke, Eric, additional, and Moore, Kathleen, additional

Published
2021
Full Text
View/download PDF

12. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Author

Trudel, Suzanne, primary, Cohen, Adam D, additional, Krishnan, Amrita Y., additional, Fonseca, Rafael, additional, Spencer, Andrew, additional, Berdeja, Jesús G., additional, Lesokhin, Alexander, additional, Forsberg, Peter A, additional, Laubach, Jacob P., additional, Costa, Luciano J., additional, Rodriguez-Otero, Paula, additional, Kaedbey, Rayan, additional, Richter, Joshua, additional, Mateos, Maria-Victoria, additional, Thomas, Sheeba K, additional, Wong, Chihunt, additional, Li, Mengsong, additional, Choeurng, Voleak, additional, Vaze, Anjali, additional, Samineni, Divya, additional, Sumiyoshi, Teiko, additional, Cooper, James, additional, and Harrison, Simon J, additional

Published
2021
Full Text
View/download PDF

13. Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Author

Cohen, Adam D., primary, Harrison, Simon J, additional, Krishnan, Amrita, additional, Fonseca, Rafael, additional, Forsberg, Peter A, additional, Spencer, Andrew, additional, Berdeja, Jesus G., additional, Laubach, Jacob P., additional, Li, Mengsong, additional, Choeurng, Voleak, additional, Vaze, Anjali, additional, Samineni, Divya, additional, Sumiyoshi, Teiko, additional, Cooper, James, additional, Fine, Bernard M, additional, and Trudel, Suzanne, additional

Published
2020
Full Text
View/download PDF

14. Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Author

Nakamura, Rin, primary, Lear, Sean, additional, Wilson, Deanna, additional, Koeppen, Hartmut, additional, Vaze, Anjali, additional, Trudel, Suzanne, additional, Spencer, Andrew, additional, Harrison, Simon J, additional, Cohen, Adam D., additional, Fine, Bernard M, additional, Li, Mengsong, additional, Cooper, James, additional, and Sumiyoshi, Teiko, additional

Published
2020
Full Text
View/download PDF

15. Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer

Author

Kalinsky, Kevin, primary, Juric, Dejan, additional, Bedard, Philippe L., additional, Oliveira, Mafalda, additional, Cervantes, Andres, additional, Hamilton, Erika, additional, Krop, Ian E., additional, Turner, Nick, additional, Schmid, Peter, additional, Varga, Andrea, additional, Italiano, Antoine, additional, Veitch, Zachary, additional, Saura, Cristina, additional, Gambardella, Valentina, additional, Cheeti, Sravanthi, additional, Kotani, Naoki, additional, Lei, Guiyuan, additional, Hutchinson, Katherine E., additional, Royer-Joo, Stephanie, additional, Vaze, Anjali, additional, Schutzman, Jennifer L., additional, and Jhaveri, Komal, additional

Published
2020
Full Text
View/download PDF

16. Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Author

Juric, Dejan, primary, Kalinsky, Kevin, additional, Oliveira, Mafalda, additional, Cervantes, Andres, additional, Bedard, Philippe, additional, Krop, Ian, additional, Hamilton, Erika, additional, Schmid, Peter, additional, Varga, Andrea, additional, Turner, Nick, additional, Italiano, Antoine, additional, Saura, Cristina, additional, Gambardella, Valentina, additional, Veitch, Zachary, additional, Dickmann, Leslie, additional, Kotani, Naoki, additional, Fredrickson, Jill, additional, Kapp, Amy, additional, Hutchinson, Katie, additional, Royer-Joo, Stephanie, additional, Vaze, Anjali, additional, Schutzman, Jennifer, additional, and Jhaveri, Komal, additional

Published
2020
Full Text
View/download PDF

17. Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer

Author

Jhaveri, Komal, primary, Kalinsky, Kevin, additional, Bedard, Philippe, additional, Cervantes, Andres, additional, Saura, Cristina, additional, Krop, Ian, additional, Hamilton, Erika, additional, Schmid, Peter, additional, Varga, Andrea, additional, Turner, Nick, additional, Italiano, Antoine, additional, Gambardella, Valentina, additional, Veitch, Zachary, additional, Oliveira, Mafalda, additional, Dickmann, Leslie, additional, Kotani, Naoki, additional, Kapp, Amy, additional, Hutchinson, Katie, additional, Royer-Joo, Stephanie, additional, Vaze, Anjali, additional, Schutzman, Jennifer, additional, and Juric, Dejan, additional

Published
2020
Full Text
View/download PDF

18. Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Author

Gerber, David E., primary, Infante, Jeffrey R., additional, Gordon, Michael S., additional, Goldberg, Sarah B., additional, Martín, Miguel, additional, Felip, Enriqueta, additional, Martinez Garcia, Maria, additional, Schiller, Joan H., additional, Spigel, David R., additional, Cordova, Julie, additional, Westcott, Valerie, additional, Wang, Yulei, additional, Shames, David S., additional, Choi, YounJeong, additional, Kahn, Robert, additional, Dere, Randall C., additional, Samineni, Divya, additional, Xu, Jian, additional, Lin, Kedan, additional, Wood, Katie, additional, Royer-Joo, Stephanie, additional, Lemahieu, Vanessa, additional, Schuth, Eva, additional, Vaze, Anjali, additional, Maslyar, Daniel, additional, Humke, Eric W., additional, and Burris, Howard A., additional

Published
2020
Full Text
View/download PDF

19. Abstract CT036: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study

Author

Moore, Kathleen, primary, Hamilton, Erica P., additional, Burris, Howard A., additional, Barroilhet, Lisa M., additional, Gutierrez, Martin, additional, Wang, Judy S., additional, Patel, Manish R., additional, Birrer, Michael J., additional, Flanagan, W. Mike, additional, Wang, Yulei, additional, Garg, Amit, additional, Lu, Xuyang, additional, Vaze, Anjali, additional, Amin, Dilip, additional, Leipold, Douglas, additional, Commerford, S. Renee, additional, Humke, Eric W., additional, and Liu, Joyce F., additional

Published
2018
Full Text
View/download PDF

20. [O2-17-03]: A PHASE I STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RO7105705 IN HEALTHY VOLUNTEERS AND PATIENTS WITH MILD-TO-MODERATE AD

Author

Kerchner, Geoffrey A., primary, Ayalon, Gai, additional, Brunstein, Flavia, additional, Chandra, Priya, additional, Datwani, Akash, additional, Fuji, Reina N., additional, Manser, Paul T., additional, Vaze, Anjali, additional, Ward, Michael, additional, Wildsmith, Kristin R., additional, and Foo-Atkins, Corinne, additional

Published
2017
Full Text
View/download PDF

21. Abstract CT009: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study

Author

Liu, Joyce F., primary, Moore, Kathleen N., additional, Wang, Judy S., additional, Patel, Manish, additional, Birrer, Michael J., additional, Hamilton, Erika, additional, Barroilhet, Lisa, additional, Flanagan, William M., additional, Wang, Yulei, additional, Garg, Amit, additional, Lu, Xuyang, additional, Vaze, Anjali, additional, Amin, Dilip, additional, Leipold, Doug, additional, Commerford, S Renee, additional, Humke, Eric W., additional, and Burris, Harold A., additional

Published
2017
Full Text
View/download PDF

22. A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).

Author

Banerjee, Susana N., primary, Oza, Amit M., additional, Birrer, Michael J., additional, Hamilton, Erika Paige, additional, Hasan, Jurjees, additional, Leary, Alexandra, additional, Moore, Kathleen N., additional, Mackowiak-Matejczyk, Beata, additional, Pikiel, Joanna, additional, Ray-Coquard, Isabelle, additional, Trask, Peter, additional, Lin, Kedan, additional, Vaze, Anjali, additional, Choi, YounJeong, additional, Marsters, Jim, additional, Maslyar, Daniel J., additional, Lemahieu, Vanessa, additional, Wang, Yulei, additional, Humke, Eric William, additional, and Liu, Joyce F., additional

Published
2016
Full Text
View/download PDF

26. A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Author

Herrera, Alex F., Patel, Manish R, Burke, John M., Advani, Ranjana H., Cheson, Bruce D., Sharman, Jeffrey P., Penuel, Elicia, Polson, Andrew G., Leng, Ning, Li, Chunze, Schuth, Eva, Vaze, Anjali, Samineni, Divya, Elstrom, Rebecca, and Diefenbach, Catherine S

Abstract

Background:CD79b is expressed by nearly all B-NHL. DCDS0780A is a THIOMABä antibody drug conjugate consisting of the potent anti-mitotic agent, monomethyl auristatin E (MMAE), conjugated to a humanized IgG1 anti-human CD79b monoclonal antibody via a protease-labile linker. THIOMABTMtechnology allows an essentially homogeneous product from the conjugation of two drugs per antibody to engineered cysteine residues. We conducted a Phase I study to assess the safety, tolerability, recommended Phase II dose (RP2D), pharmacokinetics (PK), and biologic activity of DCDS0780A alone or in combination with rituximab in pts with relapsed/refractory B-NHL.

Published
2017
Full Text
View/download PDF

27. Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm.

Author

Jasmanda Wu, Ling Zhang, Vaze, Anjali, Lin, Stephen, and Juhaeri, Juhaeri

Subjects
*WERNICKE'S encephalopathy, *MYELOPROLIFERATIVE neoplasms, *HEART diseases, *THERAPEUTICS, *MEDICAL databases, *COMPARATIVE studies, *MEDICAL care, *PATIENTS, *DISEASE risk factors
Abstract

The objectives of the study were to estimate the incidence of Wernicke's encephalopathy (WE) and cardiac disorders among patients with myeloproliferative neoplasms (MPN), and compare it with those without MPN. A total of 39,761 MPN patients were identified from the US Marketscan database. Approximately 27% of them were 65+ years of age, and 51% were male. Patients with MPN had higher rates of WE, compared to those without MPN (MPN vs. non-MPN: 1.09 vs. 0.39/1000 person-year, adjusted HR = 2.19, 95%CI 1.43-3.34). Patients with MPN also had higher rates of cardiac events (congestive heart failure: MPN vs. non-MPN: 9.27 vs. 3.70/1000 person-year, adjusted HR= 1.64, 95%CI 1.42-1.88; acute myocardial infarction: MPN vs. non-MPN: 10.45 vs. 5.02/1000 person-year, adjusted HR = 1.44, 95%CI 1.27, 1.63; cardiac arrhythmia: MPN vs. non-MPN: 106.5 vs. 53.9/1000 person-year, adjusted HR= 1.42, 95%CI 1.36-1.48). Physicians who care for patients with MPN should be aware of increased risk of WE and cardiac disorders in this population. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results